25 May 2013
Keywords: biovitrum, enters, nordic, benefix, co-promo, deal, stockholm
Article | 13 August 2007
Stockholm, Sweden-based Biovitrum has entered into a new agreement with US drug major Wyeth to co-promote BeneFIX, coagulation factor IX
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 August 2007
24 May 2013
© 2013 thepharmaletter.com